Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 8/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.69 |
| ▸ | DYRK2 | Q92630 | 7/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.69 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.69 |
| ▸ | CISD1 | Q9NZ45 | 5/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.69 |
| ▸ | MTOR | P42345 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | MAOB | P27338 | 2/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | CLK3 | P49761 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358448 | 0.82 | CISD1 (1.00) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL16416224 | 0.82 | CISD1 (1.00) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL668617 | 0.82 | CISD1 (1.00) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL668616 | 0.82 | CISD1 (1.00) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL13739026 | 0.77 | PIK3CA (0.76) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL27224263 | 0.77 | PIK3CA (0.76) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL24904264 | 0.75 | CSNK2A2 (0.64) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL30363450 | 0.75 | CSNK2A2 (0.64) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL7510151 | 0.73 | CSNK2A2 (0.45) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 | |
| SCHEMBL6785387 | 0.73 | IGF1R (0.67) | CLK1DYRK1ADYRK2DYRK1BCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-106211755-B | Cancer treatment using a combination of ERK and RAF inhibitors | 生物医学谷探索股份有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-110799245-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2020-02-14 | — | — | CN | claimed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | claimed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | claimed |
| CN-116583532-A | Bispecific HER-2 targeting compositions and methods of making and using the same | 阿穆尼克斯制药公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-106211755-B | Cancer treatment using a combination of ERK and RAF inhibitors | 生物医学谷探索股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-111386264-A | Compounds, compositions and methods for treating T-cell acute lymphoblastic leukemia | 纽约市哥伦比亚大学理事会 | 2020-07-07 | — | — | CN | disclosed |
| CN-110799245-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-10105351-B2 | Neurofibromatoses therapeutic agents and screening for same | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-2825209-B1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIV CENTRAL FLORIDA RES FOUND INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20150065554-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2825209-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | University of Central Florida Research Foundation, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138463-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065554-A1 | NEUROFIBROMATOSES THERAPEUTIC AGENTS AND SCREENING FOR SAME | VHL, DIAPH1, TSG101 | CLK1 2086/4885DYRK1A 2041/4885DYRK2 2150/4885 |
| US-10105351-B2 | Neurofibromatoses therapeutic agents and screening for same | VHL, DIAPH1, TSG101 | CLK1 2086/4885DYRK1A 2041/4885DYRK2 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.